Prolactin and breast cancer: the need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: a review

Página do item simplificado
dc.contributor.authorBrandao, Denise Froes [UNIFESP]
dc.contributor.authorStrasser-Weippl, Kathrin
dc.contributor.authorGoss, Paul E.
dc.date.accessioned2019-01-21T10:29:19Z
dc.date.available2019-01-21T10:29:19Z
dc.date.issued2016
dc.description.abstractHyperprolactinemia, defined as a sustained elevation of prolactin (PRL) levels greater than 530 mIU/L in women and greater than 424 mIU/L in men, has been implicated for a long time in breast cancer etiology and prognosis. Elevated PRL values (approximately 2-3 times higher than the reference values) are a common adverse effect of antipsychotic medications, especially with first-generation drugs, and most antipsychotics carry a standard warning regarding PRL elevations on their US product labels. These associations foster undertreatment of serious psychiatric illnesses in both otherwise healthy patients and cancer patients. This review assesses both the preclinical and clinical evidence that has led to the hypothesis of PRL's role in breast cancer risk or breast cancer progression. It is concluded that taken together, the published data are unconvincing and insufficient to deprive cancer patients in general and breast cancer patients specifically of potentially effective antipsychotic or antidepressant medications for serious psychiatric indications. We thus call on revised medication guidelines to avoid the existing undertreatment of serious psychiatric illnesses among cancer patients based on an unproven contraindication to psychiatric medications. Cancer 2016;122:184-188. (c) 2015 American Cancer Society. This review discusses the evidence for a role of hyperprolactinemia in breast cancer risk and prognosis. New guidelines are needed for antipsychotic and antidepressant medications among cancer patients.en
dc.description.affiliationAvon International Breast Cancer Research Program, Massachusetts General Hospital Cancer Center, Boston, Massachusetts
dc.description.affiliationGlobal Cancer Institute, Boston, Massachusetts
dc.description.affiliationFederal University of Sao Paulo, Sao Paulo, Brazil
dc.description.affiliationCenter for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria
dc.description.affiliationMassachusetts General Hospital Cancer Center, Boston, Massachusetts
dc.description.affiliationHarvard Medical School, Boston, Massachusetts
dc.description.affiliationUnifespFederal University of Sao Paulo, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent184-188
dc.identifierhttps://doi.org/10.1002/cncr.29714
dc.identifier.citationCancer. Hoboken, v. 122, n. 2, p. 184-188, 2016.
dc.identifier.doi10.1002/cncr.29714
dc.identifier.issn0008-543X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/49181
dc.identifier.wosWOS:000368009600006
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofCancer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAntidepressive Agentsen
dc.subjectAntipsychotic Agentsen
dc.subjectBreast Neoplasmsen
dc.subjectDepressionen
dc.subjectProlactinPostmenopausal Womenen
dc.subjectReplacement Therapyen
dc.subjectPlasma Prolactinen
dc.subjectDepressionen
dc.subjectRisken
dc.subjectMortalityen
dc.subjectReceptoren
dc.subjectGrowthen
dc.subjectCohorten
dc.subjectDrugsen
dc.titleProlactin and breast cancer: the need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: a reviewen
dc.typeinfo:eu-repo/semantics/review
Arquivos
Coleções
EPM - Artigos